Riskpilot← Back to searchSign inGet full access2CARE4 ApS
APSActiveCVR 28964080Stenhuggervej 12Wholesale of pharmaceutical and medical goods · NACE 4646Est. 2005188 employees
Revenue 2024
DKK 1,2B
+2% vs 2023
EBITDA margin
4.2%
-39% vs 2023
Equity ratio
18.9%
Financial strength
Net profit 2024
DKK 20,3M
-58% vs 2023
| Revenue | DKK 1,2B | +2% |
| EBITDA | DKK 51,1M | -39% |
| Net profit | DKK 20,3M | -58% |
| Total assets | DKK 529,1M | +18% |
| Equity | DKK 100,1M | -4% |
| Employees | 188 | — |
Legal name
2CARE4 ApS
CVR number
28964080
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
5. august 2005
Share capital
DKK 125.000
Employees
188 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af den samlede bestyrelse i forening eller af et bestyrelsesmedlem i forening med en direktør.
Company purpose
Selskabets formål er at importere, producere, forhandle og eksportere lægemidler samt anden dermed i naturlig forbindelse stående virksomhed.
Address
Stenhuggervej 12
Phone
+4575152900
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 457.930 | 516.282 | 457.403 | 626.773 | 696.739 | 766.577 | 830.481 | 864.395 | 830.050 | 1.163.565 | 1.205.653 | 1.230.471 |
| Staff expenses | -26.637 | -33.089 | -32.056 | -25.262 | -49.052 | -49.188 | -61.473 | -65.299 | -66.873 | -69.060 | -78.643 | -85.209 |
| EBITDA | 24.371 | 25.789 | 24.602 | 44.019 | 27.449 | 41.810 | 34.659 | 19.936 | -13.561 | 63.562 | 83.775 | 51.068 |
| Depreciation & amort. | -6.656 | -9.014 | -9.947 | -12.373 | -9.836 | -10.819 | -11.886 | -10.483 | -10.121 | -11.086 | -8.398 | -10.466 |
| EBIT | 17.715 | 16.775 | 14.655 | 31.646 | 17.613 | 30.991 | 22.773 | 9.453 | -23.682 | 52.476 | 75.377 | 40.602 |
| Net financials | -6.209 | -5.039 | -4.307 | -5.019 | -2.352 | -3.925 | -2.673 | -4.210 | -3.582 | -9.168 | -12.604 | -14.434 |
| Profit before tax | 11.506 | 11.736 | 10.348 | 26.627 | 15.261 | 27.066 | 20.100 | 5.243 | -27.264 | 43.308 | 62.773 | 26.168 |
| Tax | 2.646 | 2.951 | 2.420 | 5.904 | 3.510 | 5.983 | 4.267 | 1.171 | -5.992 | 9.639 | 13.924 | 5.821 |
| Net profit | 8.860 | 8.785 | 7.926 | 20.723 | 11.751 | 21.083 | 15.833 | 4.072 | -21.272 | 33.669 | 48.849 | 20.347 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 188.732 | 189.717 | 193.040 | 244.275 | 293.212 | 314.888 | 341.533 | 331.132 | 382.321 | 441.791 | 446.709 | 529.095 |
| Equity | 9.896 | 18.681 | 26.079 | 29.871 | 21.750 | 42.833 | 58.667 | 62.739 | 41.467 | 75.136 | 104.735 | 100.082 |
| Long-term debt | 7.058 | 6.530 | 5.944 | 8.810 | 7.735 | 6.656 | 6.318 | 7.776 | 27.838 | 17.658 | 295 | 1.073 |
| Short-term debt | 168.225 | 155.452 | 151.703 | 191.517 | 252.161 | 258.115 | 260.543 | 238.731 | 292.366 | 331.943 | 323.752 | 410.538 |
| Total debt | 175.283 | 161.982 | 157.647 | 200.327 | 259.896 | 264.771 | 266.861 | 246.507 | 320.204 | 349.601 | 324.047 | 411.611 |
EBITDA margin
4.2%
This company
15.8%
Market median
-73% vs market
20132024
Equity ratio
18.9%
This company
38.2%
Market median
-51% vs market
20132024
Return on equity
20.3%
This company
18.4%
Market median
+10% vs market
20132024
Net profit margin
1.7%
This company
8.1%
Market median
-79% vs market
20132024
Asset turnover
2.33×
This company
1.12×
Market median
+108% vs market
20132024
Debt / equity
4.29×
This company
0.62×
Market median
-592% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TH Management | Management | 2024 | — | — |
UE Chief Executive Officer | Chief Executive Officer | 2019 | — | — |
TB Management | Management | 2018 | — | — |
ES Chief Executive Officer | Chief Executive Officer | 2026 | — | — |
HB Management | Management | 2005 | — | — |
HF Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
2care4 Group ApS | Company | 100.0% | 100.0% | 2008 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HØJFELDT HOLDING ApS
2CARE4 ApS Board members of 2CARE4 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Hjarsbæk Rasmussen | Management | 0 companies |
| Ulrik Ernst Rasmussen | Chief Executive Officer | 0 companies |
| Torben Børsting | Management | 0 companies |
| Erik Sandberg | Chief Executive Officer | 0 companies |
| Henrik Bisgaard Jensen | Management | 0 companies |
| Henrik Fomsgaard-Knudsen | Chief Executive Officer | 0 companies |
| Toke Værndal | Board of Directors | 0 companies |